Regulatory News Release
4 July 2023
Croda successfully completes acquisition of Solus Biotech
Croda International Plc ('Croda') today confirms that, following receipt of unconditional approval from the South Korean regulatory authorities, it has now successfully completed the acquisition of Solus Biotech, a global leader in premium, biotechnology-derived active ingredients for beauty care and pharmaceuticals.
This follows the announcement on 6 February 2023 that Croda had reached an agreement to acquire Solus Biotech.
-ENDS-
Further information:
Investors: David Bishop, Croda +44 7823 874428
Media: Charlie Armitstead, Teneo +44 7703 330269
About Croda:
Croda is the company that uses smart science to create high performance ingredients and technologies that improve lives. For more information see: www.croda.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
